Novartis – media

Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis

Novartis’ Cosentyx has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA). NICE has recommended Cosentyx (secukinumab) as an option for the treatment of active nr-axSpA with objective signs of inflammation that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. The IL-17A inhibitor is recommended only if tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough. “Axial SpA is a painful and progressive long-term condition affecting approximately one in 200 people in the UK,” said Dale Webb, chief executive of the UK’s National Axial Spondyloarthritis Society (NASS). “Axial SpA can result in long-term pain, impaired mobility and fatigue. Earlier diagnosis and treatment can have a significant impact on the progression of the condition and people’s long-term outcomes, and NASS welcomes new treatment options,” he added. The ...
- Source: drugdu
- 238
- June 21, 2021
Novartis
Novartis UK signs digital partnership with Cievert for chronic disease management 29th March 2021

Novartis UK and digital health company Cievert have announced a digital innovation partnership to help streamline the management of rheumatological and dermatological diseases. The initiative aims to support patient care in rheumatology and dermatology by utilising patient-reported data and allowing clinicians to prioritise appointments on a needs-based model of care. The partnership, which was identified via the Novartis BIOME selection procedure, will see Novartis and Cievert work closely with the NHS to launch pilot programmes across the UK. The digital platform will aim to collaborate with patients, healthcare professionals (HCPs) and the NHS across the UK and support them in three areas. Firstly, the partnership will aim to capture patient digital health records in one platform to reduce misalignment among healthcare teams. Secondly, the programme will aim to coordinate and prioritise appointments based on patient need, rather than routinely scheduled reviews. Lastly, the initiative will collect real-time patient data in ...
- Source: drugdu
- 300
- March 29, 2021
Novartis
Novartis’s Alpelisib Treats Advanced Breast Cancer

Finding the ultimate treatment for breast cancer is still a dream for all the pharma companies worldwide. At present, only hormonal therapy, Pfizer’s Ibrance, Eli Lilly’s Verzenio and Novartis’s Kisqali are available for breast cancer treatment.
- Source: Reuters
- 889
- August 24, 2018
breast cancer Company Insight Novartis
Novartis Extends Donation of Egaten® (triclabendazole) Until 2022

Novartis has renewed its memorandum of understanding with the World Health Organization (WHO) to lengthen its drug donation for Egaten® (triclabendazole) to 2022 and continues its war against liver fluke. WHO lists Egaten as the only medicine for fascioliasis and also includes it in the Model List of Essential Medicines.
- Source: World Pharma News
- 935
- July 30, 2018
Company Insight Novartis WHO
Novartis Neuroendocrine Tumor App Featured in iStore

In a recent launch, Novartis’ Galaxies of Hope neuroendocrine tumor app received an additional bump from Apple. The “Featured App” status in the first week itself helped in receiving positive reviews and downloads for the community-building app.
- Source: FiercePharma
- 792
- July 25, 2018
Company Insight mHealth Novartis
Novartis Prepare Case for Earlier Kisqali Use

On Sunday, at the American Society of Clinical Oncology’s annual meeting, Novartis revealed the final outcome, showing that among patients with HR-positive, HER2-negative breast cancer, adding Kisqali to fulvestrant kept the disease away for eight months longer than fulvestrant alone.
- Source: Ddu
- 611
- June 4, 2018
cancer Company Insight Novartis
Novartis’ Afinitor Disperz wins new TSC-related approval

Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
- Source: pharmatimes
- 736
- April 12, 2018
Afinitor Disperz New Approvals Novartis TSC
Science 37 and Novartis Sign Strategic Alliance to Advance Decentralized Clinical Trials

Science 37, a trailblazing company focused on “site-less” clinical trials, announced today a strategic alliance with Novartis that will support the development of its new decentralized clinical trial (DCT) offerings. This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services.
- Source: Science 37
- 570
- March 12, 2018
Company Insight digital health Novartis
Pear Therapeutics and Novartis Will Collaborate on Prescription-Strength Apps

Boston-based startup Pear Therapeutics will link with Novartis to develop prescription-strength digital interventions for schizophrenia and multiple sclerosis (MS).
- Source: HCANews
- 762
- March 2, 2018
Company Insight digital health mHealth Novartis
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.
- Source: Prnewswire
- 605
- February 1, 2018
achondroplasia infigratinib (BGJ398) Market Views Novartis QED Therapeutics

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.